Treatment of hematologic disorders
AssigneeThe General Hospital Corporation
InventorsMegan Sykes, Thomas R. Spitzer
Life of this patent
Estimating the term…
Abstract
The inventors have discovered that hematologic disorders, e.g., both neoplastic (hematologic cancers) and non-neoplastic conditions, can be treated by the induction of mixed chimerism using myeloreductive, but not myeloablative, conditioning. Methods of the invention reduce GVHD, especially GVHD associated with mismatched allogeneic or xenogeneic donor tissue, yet provide, for example, significant graft-versus-leukemia (GVL) effect and the like.
Claims36
A method of treating a subject having a hematologic disorder comprising:
- administering a myeloreductive non-myeloablative treatment to the subject in sufficient amount such that mixed hematopoietic chimerism can be induced in the subject, and
- introducing into the subject, allogeneic donor hematopoietic stem cells (donor stem cells) to form chimeric bone marrow in the subject.
A method of treating a subject having a hematologic disorder comprising:
- administering a myeloreductive and immunosuppressive treatment to the subject in sufficient amount such that mixed hematopoietic chimerism can be induced in the subject, and
- introducing into the subject, allogeneic donor hematopoietic stem cells (donor stem cells) to form stable mixed chimeric bone marrow in the subject.
A method of treating a patient having neoplastic hematopoetic disorder, comprising:
- identifying a patient having a neoplastic hematopoetic disorder,
- administering a myeloreductive non-myeloablative treatment to the subject in sufficient amount such that macroscopic mixed chimerism can be induced in the subject, and
- introducing into the subject, allogeneic donor hematopoietic cells (donor stem cells) to form chimeric bone marrow in the subject and induce a graft-versus-leukemia response and/or graft-versus-lymphoma response, which donor stem cells are mismatched, with respect to the patient, at one or more HLA-A, B or DR antigens.
The use of donor allogeneic hematopoietic cells in the manufacture of a medicament for the treatment of a hematologic disorder, said medicament administered to a patient conditioned with myeloreductive non-myeloablative treatment, and in an amount sufficient to form chimeric bone marrow in the subject.
Dependencies are inferred from the claim text.